Strengthening the Effectiveness of the Candidate Influenza Vaccine by Combining Conserved Sequences of Hemagglutinin and M2 protein

The development of universal influenza vaccine - a vaccine directed to all subtypes of human influenza A viruses - is the really actual problem task. This paper presents the comparative characteristic of the specific activity of various recombinant proteins consisting of antigenic determinants of influenza A virus - the ectodomain of the M2 protein (M2e) and a fragment of the second subunit of the hemagglutinin (the amino acid sequence 76 - 130). Flagellin - Salmonella typhimurium protein was used as carrier protein and as adjuvant. We use two forms of flagellin: full size and with deleted hypervariable region. The proteins showed high immunogenicity, and the ability to prevent lethal infection of influenza virus in mice. Full-length flagellin with HA2 (76 - 130) and M2e on the C-terminus (protein Flg-HA2-4M2e) demonstrated the most protective properties. It provides 100% survival immunized mice that were challenge with a high dose of influenza A (H3N2) - 10 LD50. Proteins containing only full sized flagellin with M2e or flagellin truncated form with M2e at the C-terminus and HA2 within the hypervariable region, protected 75% of animals from lethal infection. Protein Flg-HA2-4M2e is promising for further study as a vaccine.

грипп, вакцинация, рекомбинантный белок, иммуногенность, протективность, influenza, vaccination, recombinant protein, immunogenicity, protection

1. Sette A., Rappuoli R. Reverse vaccinology: Devecoping vaccines in the Era of Genomicsa. Immunity. 2010; 33 (4): 530 - 541.

2. Ebrahimi S., Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes. 2011; 42: 1 - 8.

3. Fiers W., De Filette M., El Bakkouri K., Schepens B. et al. M2e-based universal influenza A vaccine. Vaccine. 2009; 27: 6280 - 6283.

4. Stepanova L., Kotlyarov R., Kovaleva A., Potapchuk M., Sergeeva M., Tsybalova L. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin. PLoS ONE. 2015; 10 (3): 22.

5. Wang L., Hess A., Chang T., Wang Y. Wang Y.C., Champion J.A., Compans R.W. et al. Nanoclusters self-assembled from conformation-stabilized influenza m2e as broadly cross-protective influenza vaccines. Nanomedicine. 2013; 10: 473 - 482.

6. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal m2 ectodomain-based influenza a vaccines: Preclinical and clinical developments. Expert Rev. Vaccine. 2009; 8: 499 - 508.

7. Turley C., Rupp R., Johnson C., Taylor D., Wolfson J. et al. Safety and immunogenicity of a recombinant m2e-flagellin influenza vaccine (stf2.4xm2e) in healthy adults. Vaccine. 2011; 29: 5145-5152.

8. Wang, T., Tan, G., Hai R., Pica N., Ngai L., Ekiert D.C.et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. USA. 2010; 107: 18979 - 18984.

9. Corti D., Suguitan A., Pinna D., Silacci C., Fernandez-Rodriguez B.M., Vanzetta F. et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 2010; 120: 1663 - 1673.

10. Zang H., Wang L., Compans R., Wang B. Universal Influenza Vaccines, a Dream to Be Realized Soon. Viruses. 2014; 6 (5): 1974 - 1991.

11. Steel J., Lowen A., Wang T., Yondola M. Gao Q,, Haye K, et al. Influenza virus vaccine based on the conserved haemagglutinin stalk domain. MBio. 2010; 1: 1 - 9.

12. Zhou L., Ren R., Yang L., Bao C., Wu J., Wang D. et al. Sudden increase in human infection with avian influenza A(H7N9) virus in China, Semptember-December 2016 Western Pac Surveill Response J. 2017; 8 (1): 1 - 9.

13. Ekiert D., Friesen R., Bhabha G., Kwaks T., Jongeneelen M., Yu W. et al. A highly conserved neutralizing epitope on group 2 influenza a viruses. Science. 2011; 333: 843 - 850.

14. Gocnik M., Fislova T., Mucha V., Sladkova T. et al. J. of General virology. 2008; 89: 958 - 967.

15. Tsybalova L., Stepanova L., Kuprianov V., Blokhina E., Potapchuk M., Korotkov A. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e. Vaccine. 2015; 05: 3398 - 3406.

16. Bates J., Aaron H., James P., Jason M. Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88. J. Immunol. 2011; 186 (11):6255 - 62.

17. Jegerlehner N., Schmitz T., Storni M., Bachmann J. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004; 172: 5598 - 5605.